BeyondSpring (BYSI) Retained Earnings (2015 - 2026)
BeyondSpring (BYSI) posted Retained Earnings of -$410.6 million for Q1 2026, down 0.53% sequentially from -$408.4 million in Q4 2025, and down 1.9% YoY from -$418.5 million in Q1 2025.
BeyondSpring (BYSI) Retained Earnings (2015 - 2026) Analysis & Trends
BeyondSpring has reported Retained Earnings for 12 years, with the latest figure at -$410.6 million in Q1 2026.
- Quarterly Retained Earnings fell 1.9% year-over-year to -$410.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$410.6 million (down 1.9% YoY) and the FY2025 annual result came in at -$408.4 million, changed 0.25% from the prior year.
- Retained Earnings eased to -$410.6 million in Q1 2026 per BYSI's latest filing, from -$408.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at $368.5 million in Q2 2022 and troughed at -$410.6 million in Q1 2026.
- A 5-year average of -$330.5 million and a median of -$403.6 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings slumped 71654.49% in 2022, then declined 0.25% in 2025.
- Over 5 years, Retained Earnings stood at -$375.3 million in 2022, then slipped by 5.6% to -$396.3 million in 2023, then slipped by 2.81% to -$407.4 million in 2024, then retreated by 0.25% to -$408.4 million in 2025, then fell by 0.53% to -$410.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$410.6 million, -$408.4 million, and -$406.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -411.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -411.44 Mn |
| Mar 31, 2026 | -410.59 Mn |
| Dec 31, 2025 | -408.43 Mn |
| Sep 30, 2025 | -406.29 Mn |
| Jun 30, 2025 | -404.75 Mn |
| Mar 31, 2025 | -402.95 Mn |
| Dec 31, 2024 | -407.43 Mn |
| Jun 30, 2024 | -403.56 Mn |
| Dec 31, 2023 | -396.30 Mn |
| Jun 30, 2023 | -388.00 Mn |
| Dec 31, 2022 | -375.28 Mn |
| Jun 30, 2022 | 368.47 Mn |
| Dec 31, 2021 | -523,000.00 |
| Sep 30, 2021 | 371.21 Mn |
| Jun 30, 2021 | 369.78 Mn |
| Mar 31, 2021 | 367.56 Mn |
| Dec 31, 2020 | -297,000.00 |
| Sep 30, 2020 | 284.31 Mn |
| Jun 30, 2020 | 277.62 Mn |
| Mar 31, 2020 | 250.42 Mn |